Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer

Shelley Dranko, Connie Kinney, Ramesk K Ramanathan

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Cetuximab is a monoclonal antibody that specifically blocks the epidermal growth factor receptor pathway. Cetuximab is now a standard drug to treat refractory advanced colorectal cancer.The most common side effect is a rash, seen in most patients. Ocular toxicity is uncommon. We report 2 cases of ocular toxicity characterized by blepharitis and conjunctivitis related to cetuximab administration. Strategies for management are discussed.

Original languageEnglish (US)
Pages (from-to)224-225
Number of pages2
JournalClinical Colorectal Cancer
Volume6
Issue number3
StatePublished - 2006
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Blepharitis
Conjunctivitis
Exanthema
Epidermal Growth Factor Receptor
Monoclonal Antibodies
Pharmaceutical Preparations
Cetuximab

Keywords

  • Blepharitis
  • Epidermal growth factor receptor
  • Erythema
  • Itchiness
  • Tearing
  • Trichomegaly

ASJC Scopus subject areas

  • Oncology

Cite this

Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer. / Dranko, Shelley; Kinney, Connie; Ramanathan, Ramesk K.

In: Clinical Colorectal Cancer, Vol. 6, No. 3, 2006, p. 224-225.

Research output: Contribution to journalArticle

@article{e58d6a8942254035a24273acb73ce618,
title = "Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer",
abstract = "Cetuximab is a monoclonal antibody that specifically blocks the epidermal growth factor receptor pathway. Cetuximab is now a standard drug to treat refractory advanced colorectal cancer.The most common side effect is a rash, seen in most patients. Ocular toxicity is uncommon. We report 2 cases of ocular toxicity characterized by blepharitis and conjunctivitis related to cetuximab administration. Strategies for management are discussed.",
keywords = "Blepharitis, Epidermal growth factor receptor, Erythema, Itchiness, Tearing, Trichomegaly",
author = "Shelley Dranko and Connie Kinney and Ramanathan, {Ramesk K}",
year = "2006",
language = "English (US)",
volume = "6",
pages = "224--225",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer

AU - Dranko, Shelley

AU - Kinney, Connie

AU - Ramanathan, Ramesk K

PY - 2006

Y1 - 2006

N2 - Cetuximab is a monoclonal antibody that specifically blocks the epidermal growth factor receptor pathway. Cetuximab is now a standard drug to treat refractory advanced colorectal cancer.The most common side effect is a rash, seen in most patients. Ocular toxicity is uncommon. We report 2 cases of ocular toxicity characterized by blepharitis and conjunctivitis related to cetuximab administration. Strategies for management are discussed.

AB - Cetuximab is a monoclonal antibody that specifically blocks the epidermal growth factor receptor pathway. Cetuximab is now a standard drug to treat refractory advanced colorectal cancer.The most common side effect is a rash, seen in most patients. Ocular toxicity is uncommon. We report 2 cases of ocular toxicity characterized by blepharitis and conjunctivitis related to cetuximab administration. Strategies for management are discussed.

KW - Blepharitis

KW - Epidermal growth factor receptor

KW - Erythema

KW - Itchiness

KW - Tearing

KW - Trichomegaly

UR - http://www.scopus.com/inward/record.url?scp=33750199017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750199017&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 224

EP - 225

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 3

ER -